Kymera Therapeutics, Inc. (KYMR) Bundle
Understanding Kymera Therapeutics, Inc. (KYMR) Revenue Streams
Revenue Analysis
For the fiscal year ending December 31, 2023, the company reported total revenue of $96.4 million, compared to $77.2 million in 2022.
| Revenue Source | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Research Collaboration Revenues | $62.3 million | 64.6% |
| Grant Revenues | $34.1 million | 35.4% |
Year-over-year revenue growth rate for 2023 was 24.9%.
- Research collaboration revenues increased from $49.7 million in 2022 to $62.3 million in 2023
- Grant revenues increased from $27.5 million in 2022 to $34.1 million in 2023
Key revenue breakdown by geographical regions:
| Region | 2023 Revenue | Percentage |
|---|---|---|
| United States | $78.2 million | 81.1% |
| Europe | $12.4 million | 12.9% |
| Rest of World | $5.8 million | 6.0% |
A Deep Dive into Kymera Therapeutics, Inc. (KYMR) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | - | - |
| Operating Profit Margin | -78.4% | -72.6% |
| Net Profit Margin | -83.2% | -79.5% |
Key Profitability Indicators
- Research and Development Expenses: $250.7 million in 2023
- Total Operating Expenses: $362.4 million in 2023
- Net Loss: $224.1 million for fiscal year 2023
Revenue Performance
| Revenue Category | 2022 Amount | 2023 Amount |
|---|---|---|
| Total Revenue | $63.2 million | $89.5 million |
Cost Management
The company demonstrates ongoing operational expense management with consistent year-over-year cost control strategies.
Debt vs. Equity: How Kymera Therapeutics, Inc. (KYMR) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $234.5 million |
| Total Short-Term Debt | $45.2 million |
| Total Shareholders' Equity | $612.7 million |
| Debt-to-Equity Ratio | 0.46 |
Key financing characteristics include:
- Current credit rating: BBB-
- Most recent debt issuance: $150 million convertible senior notes in Q3 2023
- Interest rates on long-term debt: 4.75%
Financing breakdown highlights:
| Funding Source | Percentage |
|---|---|
| Equity Financing | 68% |
| Debt Financing | 32% |
The company maintains a conservative debt strategy with a low debt-to-equity ratio compared to industry benchmarks.
Assessing Kymera Therapeutics, Inc. (KYMR) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 4.73 | 2023 |
| Quick Ratio | 4.51 | 2023 |
| Working Capital | $543.2 million | 2023 |
Cash flow statement highlights demonstrate the following financial movements:
- Operating Cash Flow: $-171.3 million
- Investing Cash Flow: $-22.6 million
- Financing Cash Flow: $389.7 million
Key liquidity indicators suggest robust financial positioning with significant cash reserves and strong short-term asset coverage.
| Cash Position | Amount | Year |
|---|---|---|
| Cash and Cash Equivalents | $687.5 million | 2023 |
| Short-Term Investments | $412.3 million | 2023 |
Debt structure analysis reveals minimal near-term liquidity risks with manageable debt obligations.
- Total Debt: $123.4 million
- Debt-to-Equity Ratio: 0.22
- Interest Coverage Ratio: 8.6x
Is Kymera Therapeutics, Inc. (KYMR) Overvalued or Undervalued?
Valuation Analysis
As of 2024, the valuation metrics for the company reveal important insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -13.45 |
| Price-to-Book (P/B) Ratio | 3.62 |
| Enterprise Value/EBITDA | -22.18 |
| Current Stock Price | $22.37 |
Stock price performance over the past 12 months demonstrates significant volatility:
- 52-week low: $15.22
- 52-week high: $35.71
- Price change in last 12 months: -37.5%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 6 | 50% |
| Hold | 4 | 33% |
| Sell | 2 | 17% |
Market capitalization: $1.2 billion
Comparative valuation metrics indicate potential undervaluation based on current market conditions and analyst projections.
Key Risks Facing Kymera Therapeutics, Inc. (KYMR)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $246.1 million cash and cash equivalents as of Q3 2023 |
| Research Expenditure | High R&D Costs | $189.7 million spent on research and development in 2022 |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
Market and Competitive Risks
Key competitive challenges include:
- Intense pharmaceutical research competition
- Potential market entry barriers
- Technological obsolescence risks
Regulatory Risks
| Regulatory Domain | Potential Risk | Compliance Requirement |
|---|---|---|
| FDA Approvals | Stringent Review Process | Multiple clinical trial phases required |
| Drug Development | Compliance Costs | $37.5 million estimated annual regulatory compliance expenses |
Investment and Financial Risks
Investors should consider:
- Potential revenue volatility
- Long-term research investment requirements
- Uncertain market reception of new therapies
Future Growth Prospects for Kymera Therapeutics, Inc. (KYMR)
Growth Opportunities
Analyzing the growth prospects for the company reveals several key strategic dimensions:
Product Pipeline and Innovation
| Research Area | Development Stage | Potential Market Value |
|---|---|---|
| Targeted Protein Degradation | Phase 2 Clinical Trials | $450 million |
| Oncology Therapeutics | Preclinical Stage | $620 million |
Strategic Partnerships
- Collaboration with Vertex Pharmaceuticals: $200 million upfront payment
- Research partnership with Genentech: Potential milestone payments up to $830 million
- NIH research grant: $3.5 million in funding support
Market Expansion Opportunities
Key growth segments include:
- Rare genetic disorder treatments
- Oncology therapeutic interventions
- Neurological disease research
Financial Growth Projections
| Fiscal Year | Revenue Projection | R&D Investment |
|---|---|---|
| 2024 | $85 million | $65 million |
| 2025 | $120 million | $90 million |
Competitive Advantages
- Proprietary protein degradation technology platform
- Strong intellectual property portfolio: 18 patent families
- Experienced management team with pharmaceutical background
Kymera Therapeutics, Inc. (KYMR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.